KOL WEBINAR WITH DR. FRANK GIORDANO

GLORIA Top-Line Results of

NOX-A12 & Radiotherapy Combination

in First-Line Glioblastoma

Presented at ASCO 2022

June 10, 2022| 8:00 AM EDT / 2:00 PM CEST

© NOXXON Pharma

WEBINAR PRESENTERS

MODERATOR

Guillaume van

Renterghem

Managing Director

LifeSci Advisors

PRESENTERS

Dr. Frank Giordano

Aram Mangasarian

Chair & Director

CEO

Radiation Oncology Dept.

NOXXON Pharma

University Hospital Bonn

Lead Investigator of NOX-A12

GLORIA Phase 1/2 Study

2

Glioblastoma is a Devastating Orphan Brain Cancer where the TME Plays a Significant Role

LACK OF EFFECTIVE THERAPIES & LOW OVERALL

SURVIVAL

5Y

Orphan

Status

4%

29,000

mOS

~ 160 active

New Cases

12-15 months

clinical trials

per year1

Glioblastoma Long-Term Survival Rates

100%

100%

80%

60%

40%

18%

11%

20%

4%

0%

Diagnosis/ Trial

2-year

3-year

5-year

Entry

HIGH UNMET NEED PATIENT SEGMENTS

  • MGMT unmethylated promoter - chemotherapy ineffective
  • NOX-A12to focus on MGMT unmethylated patients
  • Incomplete resection - poor prognosis & therapeutic responses

1. In the US, UK, FR, ES, DE & IT, Global Data April 2022

3

Sources: Poon MTC, et al., Scientific Reports 2020 Vol. 10 Issue 1; Hegi ME et al. N Engl J Med 2005;352:997-1003; Global Data, ClinicalTrials.gov & NOXXON Pharma analysis, April 2022

Frank A. Giordano, MD

Professor of Radiation Oncology

Director and Chair, Department of Radiation Oncology

University Hospital Bonn

Lead Investigator of NOX-A12 GLORIA Phase 1/2 Study

Study Arms

Dose

Escalation

Cohorts

Recruitment

Completed

OLA-BEV

Cohort

Recruiting

OLA-PEM

Cohort

Recruiting

Key inclusion criteria:

  • Newly-diagnosedsupratentorial glioblastoma WHO IV
  • MGMT promoter unmethylated
  • Incomplete resection/biopsy only
  • ECOG ≤ 2

allowing completely

resected GBM with v7.0

allowing completely

resected GBM with v7.0

RT

60 Gy (2 Gy x 30)

40.05 Gy (2.67 Gy

x 15)

OLA

FU

continuous i.v. infusion at three doses (200, 400, 600 mg/week)

16

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Noxxon Pharma NV published this content on 10 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 07:32:10 UTC.